论文部分内容阅读
目的:探讨干扰素(IFN)-α/β受体启动子-408位点的单核苷酸多态性(SNP)与IFN疗效的关系。方法:应用聚合酶链反应(PCR)并基因测序法检测210例慢性乙型肝炎(CHB)患者(轻度38例、中度102例、重度70例)的IFN-α/β受体基因启动子-408位点的SNP。对210例中既往未用过IFN治疗的80例CHB患者给予聚乙二醇化干扰素α-2a or 2b(Peg-IFN-α-2a/2b)治疗48周。比较SNP与Peg-IFN疗效的关系。结果:80例患者中,IFN治疗持久应答(SR)33例(41.3%),非持久应答(NSR)47例(58.7%)。IFN-α/β受体启动子-408位点CT基因型患者干扰素治疗SR为65%(13/20),显著高于CC基因型患者干扰素治疗SR 29.5%(13/44),两者比较差异有显著性意义(χ2=7.166,P=0.007)。干扰素治疗SR组IFN-α/β-408位点等位基因C、T的频率与NSR组的频率比较差异无显著性意义(P>0.05)。结论:IFN-α/β受体启动子-408为CT杂合基因型的CHB患者可能对Pec-IFN治疗效果较好。
Objective: To investigate the relationship between IFN-α / β receptor promoter -408 single nucleotide polymorphism (SNP) and the efficacy of IFN. Methods: The IFN-α / β receptor genes were detected in 210 patients with CHB (mild 38, moderate 102, severe 70) by polymerase chain reaction (PCR) and sequencing SNP at -408 loci. Eighty-two CHB patients who had not been previously treated with IFN were treated with peginterferon alfa-2a or 2b (Peg-IFN-a-2a / 2b) for 48 weeks. The relationship between SNP and Peg-IFN efficacy was compared. Results: Of the 80 patients, 33 patients (41.3%) had long-term response (SR) to IFN and 47 (58.7%) had non-persistent response (NSR). Interferon treatment SR was 65% (13/20) in IFN-α / β receptor promoter -408CT genotype patients, which was significantly higher than that in CC genotype patients (29.5%, 13/44) The difference was significant (χ2 = 7.166, P = 0.007). IFN-α / β-408 allele C, T frequency in interferon-treated SR group had no significant difference compared with NSR group (P> 0.05). CONCLUSIONS: CHB patients with IFN-α / β receptor promoter -408 CT heterozygous may have a better treatment of Pec-IFN.